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Background
Chronic migraine (CM) affects 2% of the general popu-
lation with substantial impact on quality of life. The effi-
cacy and safety of Botox in CM was confirmed in the
phase III Research Evaluating Migraine Prophylaxis
Therapy (PREEMPT) clinical programme. Despite this,
few data exist in the real-life setting.
Aim
To evaluate the efficacy of Botox in adults with CM in
real-life setting.
Method
Adult patients with CM attending the Hull migraine
clinic were offered Botox based on clinical needs using
the PREEMPT protocol. Headache diaries were main-
tained for at least 30 days prior to and continuously after
Botox (July 2010 and January 2014). Data were extracted
for headache, migraine, and headache-free days.
A responder was defined as one with either a 50% reduc-
tion in either headache days or migraine days an incre-
ment in crystal clear days twice that of the baseline.
Results
Of a series of 331 patients, full data were available on
299 patients There was significant decrement in head-
ache and migraine days as well as similarly significant
increment in headache-free days. Responder rate was
calculated for the above mentioned 3 categories.
Discussion
Our analysis has shown that, in a real-life clinical setting,
Botox can effectively reduce headache and migraine days,
and increase crystal clear days from baseline. Our cohort
represent a more severely affected population than
seen in PREEMPT study; furthermore the pre-treatment
headache days’ number was higher in our patients. We
are hoping to present the data on 500 patients as we con-
tinue to treat patients.
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